Not a great buy right now for an impatient entry: price is extended (RSI 72) and sitting just below first resistance (31.31), which skews near-term risk/reward toward “pause/pullback” rather than immediate upside.
Trend is still bullish (SMA_5 > SMA_20 > SMA_200) and Wall Street targets were raised materially (roughly $30–$36), so DAN remains attractive on dips or on a clean breakout above ~31.31.
Intellectia signals do not provide a “strong buy now” override today (no AI Stock Picker or SwingMax signal).
Clear stance: Hold / not a good buy at this exact moment; it becomes a better buy on a pullback toward ~30.00 or ~28.69 support, or after a breakout through ~31.31.
Positioning vs flow: Open-interest put/call at 0.62 is bullish (more calls outstanding than puts), but today’s volume put/call at 2.5 is bearish/defensive (puts dominated today’s trading flow).
Activity spike: Today’s option volume is ~2.12x the 30-day average, signaling elevated near-term positioning.
Volatility: 30D IV ~51.61 vs HV ~39.64 (options pricing in bigger moves than recent realized action). IV percentile ~44 and IV rank ~18.6 suggest IV is not extremely elevated versus its own history.
Net read: sentiment is mixed—longer-term positioning constructive, but near-term traders are buying protection or leaning cautious.
Technical Summary
Sell
4
Buy
11
Positive Catalysts
Analyst-driven catalyst: multiple firms raised price targets sharply in late Jan 2026, reflecting improved confidence in earnings trajectory and backlog.
Operational improvements highlighted by analysts: cost savings, stranded-cost elimination, and plant efficiencies cited as drivers of above-consensus outlook.
Potential event catalyst: UBS flagged the March 25 Capital Markets Day as a possible upside catalyst.
Technical backdrop remains bullish via moving averages, supporting continuation if resistance breaks.
No recent negative news flow (no news in the past week provided).
Neutral/Negative Catalysts
increases odds of consolidation/pullback before the next leg higher.
Setup into next report: QDEC 2025 earnings scheduled 2026-02-18 (pre-market) with EPS est. 0.32 (could act as a volatility catalyst given elevated IV vs HV).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend (late Jan 2026): broad-based price target increases and generally positive ratings.
Barclays: PT raised to $32 (from $27), Overweight.
RBC Capital: PT raised to $32 (from $26), Outperform.
Deutsche Bank: PT raised to $36 (from $33), Buy.
UBS: PT raised to $35 (from $31), Buy.
Wells Fargo: PT raised to $30 (from $24), Equal Weight (more cautious relative to peers).
Wall Street “pros” view: improving EBITDA outlook, backlog strength, cost savings, and potential aftermarket expansion.
Wall Street “cons” view: at least one major firm remains neutral (Equal Weight) and the stock is approaching near-term technical resistance after a run, reducing immediate upside urgency.
Wall Street analysts forecast DAN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAN is 26.6 USD with a low forecast of 24 USD and a high forecast of 28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast DAN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAN is 26.6 USD with a low forecast of 24 USD and a high forecast of 28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 30.400
Low
24
Averages
26.6
High
28
Current: 30.400
Low
24
Averages
26.6
High
28
Barclays
Dan Levy
Overweight
upgrade
$27 -> $32
AI Analysis
2026-01-23
Reason
Barclays
Dan Levy
Price Target
$27 -> $32
AI Analysis
2026-01-23
upgrade
Overweight
Reason
Barclays analyst Dan Levy raised the firm's price target on Dana to $32 from $27 and keeps an Overweight rating on the shares. The firm adjusted targets in the autos and mobility group as part of a Q4 preview. Barclays continue to prefer the car markers, saying they are benefiting from "healthy" production rates and reduced electric vehicle losses.
RBC Capital
Outperform
maintain
$26 -> $32
2026-01-22
Reason
RBC Capital
Price Target
$26 -> $32
2026-01-22
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Dana to $32 from $26 and keeps an Outperform rating on the shares. The company's FY25 pre-announcement and FY26 EBITDA guidance were above consensus, driven by remaining cost saves, the elimination of stranded costs, and further plant-level efficiencies, and longer term, there is ample opportunity for Dana to expand its aftermarket business in North America, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DAN
